HBM-7008 is under clinical development by Cullinan Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HBM-7008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
HBM-7008 overview
Bi-specific monoclonal antibody is under development for the treatment of ovarian cancer, lung cancer, endometrial cancer, cervical cancer, squamous non-small cell lung cancer, cholangiocarcinoma, esophageal cancer, urothelial cell carcinoma, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, triple-negative breast cancer and solid tumor. It targets tumor necrosis factor receptor superfamily member 9 (CD137) and tumor associated antigen 1 (TAA1) and B7H4. The drug candidate is developed based on the heavy chain antibody immune cell adapter double antibody platform (HBICE). It is administered through intravenous route.
Cullinan Oncology overview
Cullinan Oncology operates as a biopharmaceutical company. It focuses on the development of targeted therapeutics to treat cancer patients. The company’s product portfolio comprises CLN-081, CLN-049, CLN-619, CLN-978 and CLN-617. It offers its products in the therapeutic area of non-small cell lung cancer, acute myeloid leukemia, cancer, solid tumors and advanced malignancies. The company works in collaboration with Taiho Pharmaceutical for the development of CLN-081, Adimab LLC to generate antibody-derived binding domains specific for CD19, CD3, and HS and Fred Hutchinson Cancer Research Center. Cullinan Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of HBM-7008’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
